New transplant recipe aims to cut Graft-Versus-Host disease in blood cancer patients
NCT ID NCT07565220
First seen May 16, 2026 · Last updated May 16, 2026
Summary
This early-phase study tests a new combination of chemotherapy drugs (thiotepa, busulfan, fludarabine) with a lower dose of post-transplant cyclophosphamide for stem cell transplants in people with certain blood cancers like leukemia and myelodysplastic syndrome. The goal is to see if this approach can reduce serious side effects like graft-versus-host disease while still controlling the cancer. About 48 adults aged 18-70 who are candidates for a matched donor transplant will participate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UMPC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15213, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.